Cystectomy often treats bladder cancer. But bladder removal surgery can help other bladder problems, too. After cystectomy, your urine may need a new route to exit your body (urinary diversion).

Johnson & Johnson (NYSE: JNJ) today announced first results from Cohort 4 of the Phase 2b SunRISe-1 study evaluating TAR-200—an intravesical gemcitabine releasing system—for patients with certain ...

Dr. Matthew Galsky highlights the impact of Imfinzi’s adjuvant approval for patients with muscle-invasive bladder cancer ...

A supplemental Biologics License Application has been submitted to the FDA for Anktiva plus BCG in papillary NMIBC.

Medtronic (NYSE:MDT) announced today that it recently submitted its Hugo surgical robot platform to the FDA for a urologic ...

The regulator has approved Imfinzi in combination with gemcitabine and cisplatin chemotherapy as a neoadjuvant treatment prior to bladder removal surgery (radical cystectomy), followed by Imfinzi as ...

Despite radical cystectomy being the standard treatment for muscle-invasive bladder cancer, sometimes a person with invasive bladder cancer may not have their entire bladder removed. Rather, they may ...

T2 and T3 tumors More aggressive T2 and T3 tumors may require more than just the removal of visible tumors. By this stage of the disease, many urologists will recommend a radical cystectomy, in which ...

Results from the Phase IIb SunRISe-1 study demonstrated a one-year duration of response with the TAR-200 intravesical ...

At the American Urological Association (AUA) that starts later this week, J&J is scheduled to report that TAR-200 achieved a ...

Oncology Media Relations [email protected]   Investor contact: Lauren Johnson [email protected] ...